What does this new Alzheimer's drug, touted by some as a 'breakthrough,' really mean for treatment of the debilitating disease?
The FDA is expected to decide whether to approve the drug in January. The agency has approved only one other similar treatment, theFor the new 18-month, randomized, double-blind trial, researchers enrolled 1,795 patients ages 50 to 90 with early Alzheimer’s.. All were randomly assigned to receive either a placebo or intravenous lecanemab.
Those on the experimental drug scored 27% better on a Alzheimer’s rating scale compared to those on the placebo. summarized a case report as saying that the drug"contributed to her brain hemorrhage after biweekly infusions of lecanemab inflamed and weakened the blood vessels."that"all the available safety information indicates that lecanemab therapy is not associated with an increased risk of death overall or from any specific cause.
Howard Fillit, MD, co-founder and chief science officer at the Alzheimer’s Drug Discovery Foundation, noted that the trial reached its primary and secondary endpoints and had what he called a “modest” effect on cognition.
Australia Latest News, Australia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
DOJ: Bothell drug dealer sentenced 10 years for involvement in 2020 drug ring takedownA Bothell man who was involved in a major drug ring bust in 2020 was sentenced to 10 years in prison on Tuesday, according to the U.S. Department of Justice (DOJ). FOX13
Read more »
Mark Cuban’s prescription drug company in talks with hospitals to fill drug shortagesThe U.S. Food and Drug Administration maintains a list of 185 drugs in short supply.
Read more »
Drug slows Alzheimer's but can it make a real difference?New data shows an experimental Alzheimer's drug modestly slowed the brain disease's inevitable worsening.
Read more »
New Alzheimer’s Drug Shows Positive Results but Side EffectsA new Alzheimer’s drug slowed cognitive decline in a study, but caused brain bleeds and swelling in some patients, furthering debate about its usefulness
Read more »
New data shows Alzheimer's drug can slow cognitive declineResearchers followed nearly 1,800 patients over the course of 18 months and found the drug 'resulted in moderately less decline on measures of cognition and function,' compared to patients who received a placebo.
Read more »
Drug slows Alzheimer's but can it make a real difference?New data shows an experimental Alzheimer's drug modestly slowed the brain disease's inevitable worsening.
Read more »